Aging is the single most important risk factor for AD (Alzheimer's disease). However, the molecular events that connect normal aging to AD are mostly unknown. The abnormal accumulation of Aβ (amyloid β-peptide) in the form of senile plaques is one of the main characteristics of AD. In the present study, we show that two members of the neurotrophin receptor superfamily, TrkA (tyrosine kinase receptor A) and p75 NTR (p75 neurotrophin receptor), differentially regulate the processing of APP (amyloid precursor protein): TrkA reduces, whereas p75 NTR activates, β-cleavage of APP. The p75 NTR -dependent effect requires NGF (nerve growth factor) binding and activation of the second messenger ceramide. We also show that normal aging activates Aβ generation in the brain by 'switching' from the TrkA to the p75 NTR receptor system. Such an effect is abolished in p75 NTR 'knockout' animals, and can be blocked by both caloric restriction and inhibitors of nSMase (neutral sphingomyelinase). In contrast with caloric restriction, which prevents the age-associated up-regulation of p75 NTR expression, nSMase inhibitors block the activation of ceramide. When taken together, these results indicate that the p75 NTRceramide signalling pathway activates the rate of Aβ generation in an age-dependent fashion, and provide a new target for both the understanding and the prevention of late-onset AD.
INTRODUCTION
AD (Alzheimer's disease) is the most prevalent form of dementia in the world. Based on the onset of the symptoms, AD is normally divided into two groups: early-(< 60 years) and late-(> 60 years) onset. Late-onset AD is a complex and heterogeneous disease that accounts for 95-97 % of all AD cases. The prevalence of late-onset AD increases during aging without reaching a plateau [1] . Because of the increasing life expectancy observed in many countries, it is estimated that in 2050 approx. 45 million individuals will be affected by AD worldwide. Even though aging is the single most important risk factor for late-onset AD, the molecular events that mediate the age-dependent effect on AD are still mostly unknown.
The abnormal accumulation of Aβ (amyloid β-peptide) in the form of senile (or amyloid) plaques and amyloid angiopathy is one of the main neuropathological hallmarks of this disorder. Additional features of postmortem-diagnosed AD are neurofibrillary tangles and diffuse loss of neurons and synapses in the neocortex, hippocampus and other subcortical regions of the brain [2, 3] . Aβ is a 39-43 amino-acid-long peptide generated by sequential proteolysis of APP (amyloid precursor protein) at β-and γ -sites [2, 3] . The β-site cleavage represents the rate-limiting step in Aβ generation and is catalysed by BACE1 (β-site APPcleaving enzyme-1) [4] . Studies from normally aged rodents, primates and humans indicate that aging is accompanied by a progressive increase in BACE1 activity in the brain [5] . An additional increase in both activity and protein levels of BACE1 is observed in postmortem AD brains when compared with agematched controls [6, 7] . Studies from transgenic mice expressing human APP indicate that the abnormal accumulation of Aβ in the brain represents an important step for the development of the Alzheimer form of neurodegeneration [8] . In addition, BACE1 'knockout' animals, which are not able to cleave APP at the β-site and generate Aβ, do not develop AD neuropathology [9, 10] .
We have shown recently [11] that the lipid ceramide regulates the rate of Aβ generation by affecting the molecular stability of BACE1. Ceramide is a second messenger involved in many biochemical and genetic events that occur during cellular senescence [12, 13] . In addition, ceramide levels are increased by more than 3-fold in the brains of AD patients when compared with agematched controls [14, 15] . Endogenous active ceramide is mostly generated by de novo synthesis or hydrolysis of SM (sphingomyelin) at the cell surface, the latter being the most important source of the active pool of ceramide [16] . Hydrolysis of SM can be produced by either nSMase (neutral sphingomyelinase) or aSMase (acidic SMase). Only nSMase generates the signalling active ceramide; aSMase is involved in SM catabolism in the lysosomal compartment [16] . The generation of ceramide in neurons is mostly regulated by p75 NTR (p75 neurotrophin receptor), which controls the activation of endogenous nSMase [17] [18] [19] . Oxidative and metabolic stresses have also been proposed as additional ways to activate nSMase, but final proof in vivo is lacking.
In the present study, we show that neurotrophin receptors TrkA (tyrosine kinase receptor A) and p75 NTR differentially regulate APP processing: TrkA reduces, whereas p75 NTR activates, β-cleavage of APP. The p75 NTR -dependent effect requires NGF (nerve growth factor) binding and activation of the second messenger ceramide. More importantly, aging controls the rate of Aβ generation by 'switching' from TrkA to p75 NTR . Such effect is abolished in p75 NTR 'knockout' animals, and can be blocked by both caloric restriction and inhibitors of nSMase. In contrast with
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caloric restriction, which prevents the age-associated up-regulation of p75 NTR expression, nSMase inhibitors block the activation of ceramide.
MATERIALS AND METHODS

Cell culture
Human neuroblastoma cells SK-N-BE, which do not express either p75
NTR or Trk receptors [20] , were stably transfected with p75 NTR , TrkA or empty vectors, and were maintained in the presence of either hygromycin (150 µg/ml) or G418 (300 µg/ml; Calbiochem) as selection markers.
For neuronal cultures, hippocampi and frontal cortices were dissected from embryonic-day 16-18 (E16-18) mice and placed in DMEM (Dulbecco's modified Eagle's medium; Gibco BRL) [21] . The tissue was mechanically dissociated by pipetting, and neurons were plated on to poly(L-lysine)-coated six-well plates (Becton Dickinson Labware) for 2 h. The medium was then changed to Neurobasal medium containing 2 % (v/v) B27 supplement (Gibco BRL) in the absence of serum or antibiotics. Cultures grown in serum-free media yielded approx. 99.5 % neurons and 0.5 % glia. Microscopically, glial cells were not apparent in cultures at the time (day 12) they were used for experimental analyses. However, some experiments were also performed in the presence of 10 µM cytosine β-D-arabinofuranoside hydrochloride (Sigma) in order to exclude any effect produced by possible proliferation of glial cells. Medium was changed every 3 days.
Animals and dietary manipulations
Male C57Bl6 mice were purchased from Harlan Sprague-Dawley and maintained under specific pathogen-free conditions until killed. Animal care was performed in accordance with Guidelines for the Ethical Care and Treatment of Animals from the Institutional Animal Care and Use Committee at the University of Wisconsin-Madison. To control caloric intake, mice were housed singly and fed less than ad libitum intakes [22] . The control group was fed 84 kcal/week (where 1 kcal ≡ 4.184 kJ) of a modified formulation of AIN-76 semi-purified diet (Harlan Teklad), which is approx. 90 % of the average ad libitum food intake of these mice. Mice on caloric restriction were restricted in their food intake from 6 weeks of age, being fed 63 kcal/week (a 32 % reduction). The restricted diet was nearly isocaloric with the control diet, but enriched in proteins, vitamins and minerals to avoid malnutrition [22] . Mice were killed and brains were immediately removed; cortices and hippocampi were separated and rapidly frozen by immersion in liquid nitrogen.
For nSMase inhibition, slow-release pellets (Innovative Research of America), containing either manumycin A (3.5 mg/ animal over a period of 2 months) or placebo, were implanted subcutaneously under isoflurane anaesthesia. No sign of infection, discomfort or distress was observed in association with implantation and treatment. During treatment, animals were allowed free access to food and water. No difference in food intake and body weight was observed between treated and control animals. Mice were killed and brains were rapidly removed for isolation of cortices and hippocampi. p75 NTR/ExonIII−/− mice [23] were obtained from The Jackson Laboratory (Bar Harbor, ME, U.S.A.). They have a targeted deletion of exon III and lack the extracellular domain responsible for neurotrophin binding. Animals are viable and fertile, but they exhibit minor deficits in the peripheral nervous system. To avoid injuries induced by reduced sensitivity, mice were housed singly and checked daily for injuries on their extremities.
Lipid labelling and extraction
Labelling of sphingolipids in SK-N-BE cells and primary neurons was performed using [9, H(N)]palmitic acid (60 Ci/mmol; NEN Life Science) as described previously [11] . For lipid extraction, cells were washed twice in PBS, scraped and extracted in chloroform/methanol (2:1, v/v). The lipid phase was dried, resuspended in chloroform and applied, together with standards, to a Silica Gel-G (EM Science) TLC plate. Plates were developed as described previously [11] ; spots were then scraped and counted in a liquid-scintillation counter.
For ceramide quantification in the brain, brain membrane extracts were analysed by both ESI-MS (electrospray ionization MS) and TLC. Identity and quantification of TLC spots was confirmed further by ESI-MS (performed at the Mass Spectrometry Facility of the University of Wisconsin Biotechnology Center). ESI-MS analysis of our samples did not reveal breakdown products of major glycosphingolipids in the membrane preparations, excluding any contamination from myelin structures/ white matter (results not shown). Pixel densities of TLC spots were calculated from scanned images with Adobe Photoshop; densitometry was performed with the EpiChemi 3 Darkroom TM (UVP Bioimaging Systems) using Labworks Image Acquisition and Analysis Software 4.5.
Antibodies and Western blot analysis
Western blot analysis was performed as described previously [11, 21] . Polyclonal antibodies against the C-terminus of APP and BACE1 were from Chemicon International and Abcam respectively. A mouse antibody against the N-terminal domain of PS1 (presenilin 1) was from Santa Cruz Biotechnologies. Polyclonal antibodies against p75 NTR and TrkA were either from Santa Cruz Biotechnologies or Promega. Polyclonal antibodies against BACE2 and TACE [TNF (tumour necrosis factor)-converting enzyme] were both from Abcam.
Pixel densities (for signal-area) of scanned images were calculated with Adobe Photoshop; densitometry (for signal-density) was analysed with the EpiChemi 3 Darkroom TM (UVP Bioimaging Systems) using Labworks Image Acquisition and Analysis Software 4.5.
Aβ determination
For Aβ determinations, cortices and hippocampi were homogenized in GTIP buffer [100 mM Tris/HCl (pH 7.6), 20 mM EDTA and 1.5 M NaCl] containing protease inhibitors, 1.5 % Triton X-100 and 0.25 % NP-40 [21] . Detergent solubilization was sufficient to resolve more than 97 % of total brain Aβ. Formic acid or guanidine extractions did not yield additional Aβ. In this regard, it is important to stress that rodent Aβ differs from human Aβ in three amino acids and does not aggregate in fibrils/plaques.
Total Aβ (1-40 plus 1-42) was quantified by standard sandwich ELISA using 9131 [for Aβ ] and 9134 [for Aβ ] as capture antibodies, and 9154 (specific for rodent Aβ) and 4G8 as biotinylated reporter antibodies (Signet Laboratories). For each sample, the levels of Aβ 40 , Aβ 42 and Aβ total were quantified in triplicate based upon standard curves run (on every ELISA plate) and then expressed as pmol of Aβ/mg of protein. The average values of endogenous Aβ total obtained for 5-month-old animals was 7.8 + − 1.1 pmol/mg of protein for cortex and 6.1 + − 0.5 pmol/ mg of protein for hippocampus. They are in the same range of values found previously [24] for endogenous Aβ total using murinespecific reporter antibodies. Aβ 42 was constantly found to be approx. 25-30 % of total Aβ values.
β-and γ -Secretase activity in vitro
Tissue homogenates from hippocampi and cortices (prepared as described above) were assayed in vitro using the QTL Lightspeed Assay (QTL Biosystems). The assay uses a specific substrate peptide in which the cleavage sites are flanked by biotin and a quencher. Cleavage of the peptide (at β-or γ -site respectively) separates the biotin-containing peptide fragment from the quencher fragment, which then becomes unable to bind the sensor or quench its fluorescence. The specific substrates were TEEI-SEVNL * DAEFK (for β-secretase cleavage) and GVV * IA * TVK (for γ -secretase cleavage;
* indicates the specific cleavage site). The assay was performed as described by the manufacturer. Each sample was analysed in duplicate at two different concentrations. In addition to the controls suggested by the manufacturer, we also assayed the samples after boiling at 100
• C for 30 min prior to incubation with the substrate and sensor. Values were calculated over background (blank; no enzyme) and expressed as arbitrary units/g of protein.
Statistical analysis
The data were analysed by ANOVA and Student's t test comparison using GraphPad InStat3 software. Statistical significance was reached at P < 0.05.
RESULTS
Neurotrophin receptors differentially regulate β-cleavage of APP
We initially analysed APP metabolism following NGF treatment in the human neuroblastoma SK-N-BE cell line expressing either p75 NTR or TrkA. Before stable transfection with p75 NTR or TrkA, the above cell line expressed neither of the receptors [20] . This is particularly relevant since NGF binding to TrkA inhibits the p75 NTR -dependent activation of ceramide [25] . NGF treatment increased both ceramide levels and the steadystate levels of β-APP-CTF (APP C-terminal fragment) in p75 NTR cells ( Figures 1A and 1C) . β-APP-CTF is the intermediate product of β-cleavage of APP and a direct indication of BACE1 activity. A parallel increase in α-APP-CTF, produced by α-cleavage of APP, was also evident ( Figure 1C) ; however, α-cleavage of APP does not lead to the generation of Aβ. NGF treatment of p75 NTRexpressing cells also increased the steady-state levels of BACE1 in the absence of any apparent effect on PS1 expression levels ( Figure 1E ). These results are consistent with our previous observation [11] that ceramide can regulate both β-and α-cleavage of APP in the absence of any effect on γ -secretase activity. The effect produced by NGF was dose-dependent and specific for p75 NTR , since it was not observed in TrkA cells, which were unable to activate the ceramide signalling pathway ( Figures 1B, 1D and 1F) . It is worth noting that, prior to NGF treatment, the baseline levels of β-APP-CTF were already higher in cells expressing p75 NTR -expressing cells were limited to α-and β-APP-CTF; no additional modifications of APP processing were observed (see Supplementary Figure 1A at http://www.BiochemJ.org/bj/391/bj3910059add.htm). The liberation of the second messenger ceramide following NGF treatment did not affect cell viability, as assessed by LDH (lactate dehydrogenase) release into the media (see Supplementary Table 1 at http://www.BiochemJ.org/bj/391/bj3910059add.htm), confirming our previous conclusions [11] further that the regulation of Total cell lysates were separated on 4-12 % Bis-Tris SDS/PAGE gels, blotted on to a PVDF membrane, and probed with antibody AB5352 against the C-terminal domain of APP. The primary antibody was followed by a horseradish-peroxidase-conjugated monoclonal antibody and detected by chemiluminescence as described previously [11, 21] . Mature (m-APP) and immature (im-APP) APP, together with β-and α-APP-CTFs, are indicated. (E and F) Western blot analysis of BACE1 and PS1-N-terminal-fragment (PS1-NTF) expression levels following NGF treatment. Total cell lysates were separated on 4-12 % Bis-Tris SDS/PAGE gels, blotted on to a PVDF membrane, and probed with either antibody ab2077 (anti-BACE) or sc-8040 (anti-PS1). The primary antibody was followed by an horseradish-peroxidase-conjugated monoclonal antibody and was detected by chemiluminescence. BACE1 and PS1-NTF are indicated.
APP processing downstream from ceramide is not secondary to the activation of the apoptotic cascade.
Next we analysed APP processing and Aβ generation in primary neurons from both WT (wild-type) and p75 NTR−/− mice in which exon III of the p75 NTR locus was targeted for deletion [23] . These mice produce a shorter isoform of p75 NTR lacking the extracellular domain of the receptor required for neurotrophin binding [26] . Ceramide levels in p75 NTR−/− neurons were found to be markedly reduced when compared with the WT counterpart ( Figure 2A) . We also observed a striking correlation between ceramide ( Figure 2A ) and Aβ levels in the conditioned media (Figure 2B) with an approx. 50 % reduction in p75 NTR−/− neurons. Manumycin A, a competitive and irreversible inhibitor of nSMase [27] , reduced both ceramide levels and Aβ secretion in WT neurons ( Figures 2A and 2B ); no effect was observed when manumycin A was administered to p75 NTR−/− neurons (Figures 2A and  2B ), indicating that nSMase acts downstream from p75 NTR (Figure 2D) . Analysis of BACE1 and APP processing was consistent with the above results showing higher steady-state levels of both BACE1 and β-APP-CTF in WT compared with p75 NTR−/− neurons ( Figure 2C) . Again, manumycin A reduced both BACE1 and β-APP-CTF levels in WT, but not in p75 NTR−/− , neurons (Figure 2C) . No overall effect was observed in the steady-state levels of either BACE2, a close homologue of BACE1, or TACE, a regulated form of α-secretase ( Figure 2C) .
When taken together, the above results obtained with human neuroblastoma cell lines and primary neurons indicate that p75 NTR can activate Aβ generation through the liberation of the second messenger ceramide (Figure 2D ), which is responsible for the molecular stabilization of BACE1 [11] .
Aging regulates Aβ generation through the p75 NTR receptor system
Neurotrophins bind to two different classes of receptors: p75 NTR and the tyrosine kinase family of receptors (TrkA, TrkB and TrkC) [28] . Our results, obtained using a genetic approach, indicate that the p75 NTR -, but not the TrkA-, dependent signalling pathway activates the biogenesis of Aβ. Previous studies with sensory and motor neurons [29, 30] have shown that aging is accompanied by a progressive increase in p75 NTR expression. The rise in p75 NTR expression is also accompanied by a parallel decrease in the expression of Trk receptors, suggesting that the differential regulation of these two classes of neurotrophin receptors underlies a common age-associated mechanism [29, 30] . Therefore our results would suggest that normal aging favours the p75 NTR -compared with the TrkA-dependent signalling event.
In order to test this hypothesis, we analysed ceramide metabolism and APP processing in normally aged mice. These experiments were all performed with non-transgenic animals because AD transgenic mice develop a severe form of neuropathology early in life and do not allow for an accurate and definitive analysis of late-life events.
Figures 3(A) and 3(B) show that normal aging of the brain is accompanied by a shift in the relative expression of TrkA and p75 NTR : p75 NTR increases whereas TrkA decreases. This effect is accompanied by a parallel increase in the levels of ceramide, BACE1, β-APP-CTF and total Aβ (Figures 3C-3F) . Analysis of cortex ( Figure 3 ) and hippocampus (see Supplementary  Figure 2 at http://www.BiochemJ.org/bj/391/bj3910059add.htm) yielded very similar results. The levels of activation of p75 NTR , ceramide, BACE1 and Aβ biosynthesis detected in both the cortex and hippocampus (approx. 1.5-fold; 30 months compared with 5 months) are in the same range normally found with other agerelated events using gene microarrays [31, 32] . In this regard, it is important to remember that patients affected by Down's syndrome (trisomy 21), who have a 50 % increase in gene dosage (extra copy of APP on chromosome 21) from birth, develop AD during their fourth decade of life. Therefore the 50-60 % gradual activation of Aβ generation observed during the normal process of aging is consistent with the progression of late-onset AD, which normally strikes during or after the seventh decade of life.
Caloric restriction is the only experimental intervention able to extend the maximum life span and to delay many biological changes that are associated with aging [33] . The ability of caloric restriction to delay or arrest the biochemical and physiological changes observed during aging has been confirmed continuously in many animals, suggesting common mechanisms that act to control the life span of all animals.
Therefore we decided to analyse whether the above events were truly under the general programming of aging by studying mice subjected to long-term caloric restriction. Our results indicated that caloric restriction was able to arrest the age-associated changes in the relative expression of neurotrophin receptors, ceramide production, BACE1 levels, APP processing and Aβ generation (Figure 3) . No effect was observed on the steady-state levels of mature and immature APP (results not shown).
In order to confirm that the effect produced by aging on APP/Aβ metabolism required activation of the p75 NTR signalling pathway, we analysed young and old p75 NTR−/− mice. Figure 4 shows that p75 NTR−/− animals were not able to raise ceramide levels in an age-dependent fashion, and did not show any increase in BACE1 levels, β-cleavage of APP and Aβ production. It is noteworthy that the levels of ceramide, BACE1, β-APP-CTF and Aβ in the knockout mice were always lower than those of their age-matched controls (Figure 4) , suggesting that the constitutive expression of p75
NTR is, at least in part, responsible for the control levels of APP/Aβ metabolism even before the additional activation produced by normal aging. This last conclusion is also supported by the results obtained with human neuroblastoma cells, where p75
NTR expression increased β-cleavage of APP even in the absence of NGF treatment (see Supplementary Figure 1B at http://www.BiochemJ.org/bj/391/bj3910059add.htm), and with those obtained with primary neurons from p75 NTR−/− animals, which showed levels of ceramide and Aβ below those of their WT counterpart (Figure 2 ).
Manumycin A prevents the age-associated activation of Aβ generation
Finally, we decided to treat normal mice with the nSMase inhibitor manumycin A. In contrast with caloric restriction that acts by affecting the relative expression of neurotrophin receptors, nSMase inhibitors block the activation of the second messenger ceramide, therefore acting downstream of p75 NTR . Manumycin A is predicted to pass the brain/blood barrier. Indeed, when administered through the diet for only 5 days, it reduced nSMase activity in brain homogenates by approx. 20 % (from 47.8 + − 5.0 to 37.4 + − 2.7 nmol of ceramide formed · h −1 · mg of protein −1 ). As expected, no effect was observed on the activity of aSMase (results not shown). Even though manumycin A was effective through the diet, we decided to deliver the inhibitor via implantable slowrelease biopolymer pellets in order to obtain a continuous and controlled release of the active compound. Manumycin A was administered to 1-, 7-and 20-month-old mice at the concentration of 3.5 mg/animal over a period of 2 months, which has already been shown not to be toxic to rodents [34, 35] .
Analysis of both cortex ( Figure 5 ) and hippocampus (results not shown) confirmed the age-associated increase in ceramide production, BACE1 levels, APP processing and Aβ generation. The results also revealed that manumycin A can successfully block the above events in an age-dependent fashion. It is worth stressing the fact that manumycin A was more effective in older mice, which show a more pronounced activation of nSMase ( Figure 5) . When administered to 20-month-old animals, manumycin A produced levels of APP processing and Aβ generation similar to p75 NTR−/− mice, which were unable to activate the ceramidedependent regulation of APP/Aβ metabolism (Figure 4 ; also see Figure 2 ). Finally, manumycin A did not produce any effect when administered to p75 NTR−/− mice ( Figure 5 ), confirming further that it acts downstream of p75 NTR .
Figure 4 Genetic disruption of p75 NTR abolishes the age-associated activation of Aβ generation
Analysis of both hippocampus (Hp) and cortex (Cx) from young and old p75 NTR−/− mice. Analysis was performed as described in the legend to Figure 3 . Results are expressed as percentage of the data for 3-month-old control animals. Error bars represent the S.D. for 12 different determinations. Statistical significance compared with 3-month-old (*) or age-matched (#) control animals is indicated.
In conclusion, the above results indicate that normal aging increases Aβ generation by acting through the p75 NTR -mediated activation of the second messenger ceramide. They also suggest that nSMase inhibitors can provide an effective strategy to prevent the age-associated risk for AD.
Only β-secretase activity (and not γ -) is under the control of the p75 NTR -ceramide pathway during aging
We have so far assumed that the increased levels of BACE1, with consequent activation of the β-cleavage of APP, are solely responsible for the effects produced by the p75 NTR -ceramide signalling pathway on Aβ generation during aging. This assumption is supported by our previous studies [11] showing that ceramide regulates α-and β-, but not γ -, cleavage of APP and by the increased levels of β-APP-CTF, which were observed in the absence of any effect on APP levels. Indeed, if the increased levels of Aβ were a consequence of increased γ -cleavage, we would expect reduced β-APP-CTF levels. Instead, the levels of Aβ were always paralleled by similar changes in both β-APP-CTF and BACE1, indicating that the rate of β-cleavage is the primary event responsible for the levels of Aβ produced during aging.
However, we cannot rule out the possibility that aging is accompanied by increased activity of both β-and γ -secretase, which could be differentially regulated. In order to address this issue, we decided to analyse γ -secretase activity from brain homogenates in vitro. As a control, we also analysed β-secretase activity using a similar enzymatic approach. The results shown in Figure 6 (A) indicate that γ -secretase activity was not significantly affected by aging, genetic disruption of p75 NTR or nSMase inhibition. In contrast, β-secretase activity increased during aging ( Figure 6B ) by approx. 50 % over a period of 19 months (from 3 to 22 months); such an effect was completely abolished by genetic disruption of the ligand-binding domain of p75 NTR and manumycin A treatment ( Figure 6B ).
When taken together, these results confirm that increased steady-state levels and activity of BACE1, the rate-limiting enzyme in the biosynthesis of Aβ, cause the activation of Aβ generation observed during aging. They also confirm that the ageassociated activation of β-secretase is under the control of the p75 NTR -ceramide molecular pathway.
DISCUSSION
In the present study, we have identified the p75 NTR system as a novel molecular link between normal aging of the brain and AD, providing a new target for both the understanding and prevention of the Alzheimer form of neurodegeneration. We have also shown that caloric restriction and nSMase inhibitors may provide efficient ways to reduce the risk associated with age. The former acts by preventing the 'switch' in the expression of neurotrophin receptors induced by aging, whereas the latter acts by blocking the activation of ceramide. In both cases the signalling pathway downstream p75 NTR and ceramide is interrupted ( Figure 7 ). While this manuscript was under preparation, Capsoni et al. [35a] have shown that deletion of p75 NTR in AD11 anti-NGF transgenic mice completely abolished both amyloid load and Mice of 1, 7, and 20 months of age were implanted with slow-release pellets containing either manumycin A (3.5 mg/animal over a period of 2 months) or placebo. Animals were killed following 2 months of treatment (at 3, 9 and 22 months of age), and were analysed as described in the legend to Aging regulates the rate of Aβ generation by controlling the relative expression of neurotrophin receptors p75 NTR and TrkA. Upon binding to NGF, p75 NTR activates nSMase and induces hydrolysis of sphingomyelin with consequent liberation of the second messenger ceramide. The ceramide-dependent signalling cascade increases the steady-state levels of BACE1, the rate-limiting enzyme in the biosynthesis of Aβ. Aβ then aggregates and precipitates in the brain in the form of senile (or amyloid) plaques. Even though the ceramide-dependent signalling cascade can also activates α-cleavage of APP (the present study and [11] ), such an event does not lead to the generation of Aβ. Caloric restriction prevents the age-associated switch from the TrkA-to p75 NTR -dependent signalling cascade. It is noteworthy that TrkA reduces APP processing and prevents Aβ generation. In contrast with caloric restriction, nSMase inhibitors block the generation of ceramide and prevent Aβ biosynthesis without affecting the expression of neurotrophin receptors.
Aβ accumulation, leading to a dramatic amelioration of AD-like neurodegeneration. Their results clearly indicate that the abnormal Aβ production and amyloid plaque accumulation in AD11 mice is produced solely by overstimulation of the p75 NTR signalling pathway, and are consistent with our present results.
Recent studies have shown that pro-NGF, the uncleaved form of NGF, binds to p75 NTR with higher affinity than mature NGF and that it prefers p75 NTR to TrkA [36] . This might be particularly relevant considering that the levels of pro-NGF found in the brain of AD patients are higher than in age-matched controls [37] , therefore elevating the risk already provided by normal aging. It is also worth noting that different studies have found a selective and marked reduction in the expression of cortical TrkA in early and late stages of AD when compared with age-matched controls [38, 39] . Conversely, the expression of p75 NTR has been found to be greatly increased in neurons of both cortex [40] and hippocampus [41] of AD patients. In addition, the latter study has also reported that the expression of p75 NTR is increased highly in hippocampal neurons containing hyperphosphorylated tau. One study on cholinergic projection neurons of the forebrain nucleus basalis [39] found an inverse relationship between TrkA expression levels and AD progression, but failed to detect any change in p75 NTR protein levels. However, the same neuronal population was also found to have increased p75
NTR levels in AD patients at both the mRNA [42] and protein [43] levels. p75 NTR is part of the large family of TNF receptors and with them shares the ability to translate both death and survival signals [44] . This may either involve different affinities to the ligand(s) [28] , in concert with co-receptors that would determine the exact message to be translated [45] , or cytoplasmic interactors, which modulate the interaction of the receptor with the 'active' signalling molecule [44, 46] . On this front, it is important to stress the fact that p75
NTR is devoid of intrinsic catalytic activity and, therefore, its signalling abilities rely on intracellular interactors. Since the ability of p75 NTR to liberate the second messenger ceramide requires activation of nSMase, the identification of the cytosolic interactors could provide additional molecular targets to use for the prevention of late-onset AD.
The ability of p75 NTR to transduce both death and life signals has also been observed in the presence of Aβ. Indeed, although some studies have shown that extracellular Aβ can trigger cell toxicity/death through p75 NTR [47, 48] , a recent study [49] has proposed a neuroprotective role for p75 NTR against extracellular Aβ toxicity in human neurons. It is worth remembering that ceramide activation downstream of p75 NTR has also been associated with neuronal survival [18, 19] . The possible implications of the above conclusions, in view of the TrkA-to-p75 NTR switch induced by aging, will need to be explored further using appropriate aging paradigms.
The identification of a TrkA-to-p75 NTR switch as a possible molecular link between normal aging of the brain and AD provides novel insights in the understanding of this form of neuropathology. The fact that the TrkA-to-p75 NTR transition is completely blocked by caloric restriction indicates that such an event is part of the general programming of aging. Therefore the molecular pathways that are involved in the regulation of life span and other basic agerelated events will need to be targeted in order to fully understand how neurotrophin signalling is regulated during aging.
